Join us for a virtual KOL Event with BioAtla, featuring Carl M. Gay, MD, PhD (MD Anderson Cancer Center) who will review the Phase 2 BA3011 data in non-small cell lung cancer (NSCLC), which will be presented at the IASLC 2023 North America Conference Dec 1 – 3.

BA3011, a conditionally and reversibly active antibody drug conjugate (ADC) targeting the receptor tyrosine kinase AXL, is currently in Phase 2 for multiple solid tumor types, including NSCLC. The event will include a discussion of AXL as a contributor of therapeutic resistance and a marker of poor prognosis in NSCLC patients, as well as review of the Phase 2 BA3011 data in refractory NSCLC.

A live question and answer session will follow the presentation.